Brynjelsen Sean's Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Aug 20, 2026
- Accession no.
- 0001437749-26-028651
- Filed
- Aug 20, 2026, 6:26 PM ET
- Trade date
- Aug 19-20, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $6.09M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brynjelsen SeanCIK 0001669976 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Common Stock | SSaleDisposed | −8,978 | $62.65 | −$562,471.7 | 1,052,216 | Direct | |
| Aug 20, 2026 | Common Stock | SSaleDisposed | −47,307 | $60.17 | −$2,846,462.19 | 1,004,909 | Direct | |
| Aug 20, 2026 | Common Stock | SSaleDisposed | −36,373 | $61.11 | −$2,222,754.03 | 968,536 | Direct | |
| Aug 20, 2026 | Common Stock | SSaleDisposed | −7,342 | $62.12 | −$456,085.04 | 961,194 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.